Windtree Therapeutics Inc (WINT)

Mar 26, 2025, 8:47 AM EDT - 8 days ago

Evofem Expects Significant Reduction in PHEXXI Manufacturing Cost Through Agreement with Windtree Therapeutics

Mar 24, 2025, 8:30 AM EDT - 10 days ago

Evofem Reports Fourth Consecutive Year of Net Sales Growth

ADTX

Mar 24, 2025, 8:00 AM EDT - 10 days ago

Windtree Therapeutics Regains Compliance with Nasdaq Listing Rules

Mar 20, 2025, 8:00 AM EDT - 14 days ago

Windtree Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product

Jan 15, 2025, 8:00 AM EST - 2 months ago

Windtree Strengthens Global Intellectual Property Portfolio with New Japanese Patent For the Company's Oncology Pipeline

Jan 13, 2025, 8:00 AM EST - 2 months ago

Windtree Announces the Addition of Leanne Kelly to Its Board of Directors

Dec 9, 2024, 8:00 AM EST - 4 months ago

Windtree Announces New Istaroxime Patent Filing for Preventing or Reducing the Risk of Acute Myocardial Arrhythmia

Dec 4, 2024, 8:00 AM EST - 4 months ago

Windtree Announces Partnership with New Growth Advisors to Leverage Positive Phase 2 Istaroxime Study in Cardiogenic Shock for a Potential Strategic Transaction

Nov 27, 2024, 4:05 PM EST - 4 months ago

Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates

Oct 23, 2024, 8:00 AM EDT - 5 months ago

Windtree Announces Istaroxime Cardiogenic Shock Patent Filings In Countries Around the World

Oct 17, 2024, 8:15 AM EDT - 6 months ago

Windtree Announces Expansion of Patents with Issuance of Istaroxime Patent for Japan

Sep 30, 2024, 8:15 AM EDT - 6 months ago

Windtree Announces Positive Phase 2b Topline Clinical Results with Istaroxime Significantly Improving Cardiac Function and Blood Pressure in Heart Failure Patients in Early Cardiogenic Shock

Sep 26, 2024, 4:05 PM EDT - 6 months ago

Windtree Therapeutics Announces Virtual Investor Day Presentation on October 1 at 3pm ET

Sep 25, 2024, 8:15 AM EDT - 6 months ago

Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

Aug 20, 2024, 4:05 PM EDT - 8 months ago

Windtree Therapeutics Reports Second Quarter 2024 Financial Results and Provides Key Business Updates

Aug 14, 2024, 4:05 PM EDT - 8 months ago

Windtree Announces New Additions and Changes to Its Board of Directors

Jul 25, 2024, 8:00 AM EDT - 9 months ago

Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data

May 7, 2024, 8:00 AM EDT - 11 months ago

Windtree Therapeutics Regains Compliance with Nasdaq

Apr 22, 2024, 11:06 AM EDT - 1 year ago

What made Windtree Therapeutics stock tank 20% on Monday?

Apr 18, 2024, 8:00 AM EDT - 1 year ago

Windtree Therapeutics Announces Reverse Stock Split

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates

Apr 8, 2024, 4:48 PM EDT - 1 year ago

Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing

Feb 1, 2024, 8:00 AM EST - 1 year ago

Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research

Jan 31, 2024, 8:00 AM EST - 1 year ago

Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives

Jan 26, 2024, 9:20 AM EST - 1 year ago

Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company

Jan 25, 2024, 8:30 AM EST - 1 year ago

Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company

Jan 18, 2024, 9:00 AM EST - 1 year ago

Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China

Jan 17, 2024, 8:00 AM EST - 1 year ago

Windtree Therapeutics Announces License Agreement with Lee's Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region

Jan 2, 2024, 4:05 PM EST - 1 year ago

Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator

Dec 19, 2023, 9:30 AM EST - 1 year ago

Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024

Dec 18, 2023, 8:00 AM EST - 1 year ago

Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

Nov 16, 2023, 8:00 AM EST - 1 year ago

Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent

Nov 9, 2023, 4:15 PM EST - 1 year ago

Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates

Nov 8, 2023, 8:00 AM EST - 1 year ago

Windtree to Present at the Sidoti Micro Cap Conference on November 16th

Oct 12, 2023, 7:30 AM EDT - 1 year ago

Windtree to Present at the ThinkEquity Conference on October 19th in New York City

Oct 10, 2023, 7:30 AM EDT - 1 year ago

Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th

Oct 3, 2023, 8:00 AM EDT - 1 year ago

Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th

Aug 23, 2023, 8:00 AM EDT - 1 year ago

Windtree Announces Issuance of Composition of Matter Patent for Dual Mechanism SERCA2a Activators by the US Patent and Trademark Office

Aug 16, 2023, 9:00 AM EDT - 1 year ago

Windtree Therapeutics (NASDAQ:WINT) Is Developing A Multi-Asset Franchise Of Its Novel SERCA2a Activators In A Multi-Billion Dollar Market

Aug 7, 2023, 4:05 PM EDT - 1 year ago

Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates

Jul 25, 2023, 9:25 AM EDT - 1 year ago

Windtree Therapeutics' (NASDAQ: WINT) Upcoming Istaroxime Development Milestones And Next Generation Drug Candidates Could Produce New Fast Follow-On Line Of Drugs For Heart Failure

Jul 18, 2023, 9:00 AM EDT - 1 year ago

The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market

Jul 14, 2023, 9:00 AM EDT - 1 year ago

Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge – Windtree Therapeutics (NASDAQ:WINT) Is Helping Change That

Jun 27, 2023, 8:00 AM EDT - 1 year ago

Windtree Therapeutics Appoints Mark Strobeck, Ph.D. to Board of Directors

Jun 12, 2023, 8:00 AM EDT - 1 year ago

Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a Group of SERCA2a Activators with a Dual Mechanism

Jun 5, 2023, 8:00 AM EDT - 1 year ago

Windtree Therapeutics to Host Virtual R&D and Investor Day Focusing on the Cardiogenic Shock Market, Istaroxime, Company Strategy and Planned Near-Term Milestones

May 15, 2023, 4:30 PM EDT - 2 years ago

Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates

Apr 27, 2023, 8:00 AM EDT - 2 years ago

Windtree Therapeutics Announces Publication from Its SEISMiC Pre Cardiogenic Shock Study Comparing Two Doses of Istaroxime

Apr 24, 2023, 4:01 PM EDT - 2 years ago

Windtree Therapeutics Announces Closing of $12.42 Million Underwritten Public Offering Including Full Exercise of Overallotment Option

Apr 20, 2023, 8:30 AM EDT - 2 years ago

Windtree Therapeutics Announces Pricing of Upsized $10.8 Million Underwritten Public Offering